Daymark Health, a company dedicated to transforming the cancer care experience for patients, healthcare providers, and health plans, has completed a significant Series A funding round, raising $20 million. This crucial investment was led by Healthier Capital and Blue Venture Fund, with continued support from existing investors including Yosemite, Maverick Ventures, and Oncology Ventures. This funding will enable Daymark to expand its innovative approach to cancer care, making a profound difference in the lives of many.
Daymark’s unique model of care extends beyond traditional clinical treatment, addressing the comprehensive needs of patients, encompassing their clinical, social, and mental health. This integrated support is delivered both virtually and within the comfort of patients’ homes, working hand-in-hand with oncologists and primary care providers.
A team of community-based clinicians complements the company’s advanced, technology-driven cancer care platform. Together, they provide essential care navigation, ensuring patients receive continuous support around the clock, access to vital mental health assistance, effective symptom management, and crucial social support. Daymark also strategically collaborates with health plans, aligning incentives to not only improve patient outcomes but also to manage the overall cost of care effectively.
This substantial $20 million financial investment from Healthier Capital and Blue Venture Fund will be instrumental in allowing Daymark Health to continue scaling its groundbreaking cancer care platform. It will also facilitate the creation of new partnerships with health plans and providers across the United States, ultimately bringing its cutting-edge technology and comprehensive care model to a greater number of patients in need.
Healthier Capital, a key investor in this round, is recognized for partnering with technology-driven innovators committed to delivering healthier outcomes for everyone. The firm was founded by Amir Dan Rubin, who previously served as CEO of One Medical, a prominent tech-enabled primary care organization now part of Amazon. Blue Venture Fund represents a unique and powerful collaboration among various Blue Cross and Blue Shield (BCBS) companies, the Blue Cross Blue Shield Association, and Sandbox. This collaboration has seen 36 BCBS companies and special purpose licensees collectively commit over $1.2 billion across five funds.
The combined investment from these influential organizations underscores a clear industry-wide recognition that oncology is currently undergoing a period of rapid and significant transformation. Both payers and providers are increasingly aligned on the urgent need for more integrated and sustainable models of care to meet the evolving demands of cancer treatment. To further bolster its leadership, Daymark Health will welcome Dr. Aman Mahajan from Healthier Capital and Kelsey Maguire from Blue Venture Fund to its board of directors.
KEY QUOTES:
“We are seeing a tipping point in oncology, where payers feel the ongoing pressures of managing specialty risk and providers are seeking solutions that put patients first. We built Daymark Health to provide compassionate, intelligent, and frictionless cancer care at scale and are honored to partner with our new investors to advance cancer care across the U.S.”
Dr. Justin Bekelman, oncologist and CEO and Co-Founder of Daymark Health
“Daymark is breaking down the silos in healthcare delivery to better enable personalized care for patients with cancer, while improving outcomes and reducing avoidable costs. Daymark is delivering a transformational model of personalized, high-quality, value-based cancer care.”
Aman Mahajan, MD, PhD, Partner at Healthier Capital
“Daymark and Blue Venture Fund are passionate about a shared purpose: to give all patients the best possible care experience, driving better health outcomes and ensuring they feel seen, heard, and valued. We’re thrilled to partner with Daymark as they redefine the cancer care experience and evolve what’s possible in value-based oncology.”
Kelsey Maguire, Managing Director at the Blue Venture Fund
